First-in-class HIF-PH inhibitor API for chronic kidney disease anemia treatment.
Roxadustat is a pioneering oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stimulates erythropoiesis by increasing endogenous erythropoietin production and improving iron availability. This API is critical for manufacturing treatments for anemia associated with chronic kidney disease (CKD), offering a potent, non-injectable alternative to traditional erythropoietin-stimulating agents (ESAs). Full cGMP and regulatory support are available.